Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments
NCT06124677
·
clinicaltrials.gov ↗
COMPLETED
Status
46
Enrollment
OTHER
Sponsor class
Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG:
Faricimab
Sponsor
Rigshospitalet, Denmark